Trial Profile
Observational Study to Assess Effect and Safety of High Dose of Biotin (Qizenday®) in Progressive Multiple Sclerosis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Sep 2021
Price :
$35
*
At a glance
- Drugs Biotin (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms BIOSEP
- 20 Sep 2021 Status changed from recruiting to completed.
- 10 Oct 2017 New trial record